Skip to search formSkip to main contentSkip to account menu

SOM-230

Known as: SOM 230, SOM230 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor… 
Review
2010
Review
2010
The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have increased in the past 20 years. GEP… 
Review
2009
Review
2009
Background  The discovery of somatostatin (SST) and the synthesis of a variety of analogues constituted a major therapeutic… 
Highly Cited
2009
Highly Cited
2009
CONTEXT There is currently no medical therapy for Cushing's disease that targets the pituitary adenoma. Availability of such a… 
Review
2008
Review
2008
  • H. Schmid
  • Molecular and Cellular Endocrinology
  • 2008
  • Corpus ID: 8975340
Highly Cited
2006
Highly Cited
2006
CONTEXT There is no tumor-directed medical therapy available for Cushing's disease. OBJECTIVE The objective was to determine… 
Highly Cited
2005
Highly Cited
2005
In a series of human corticotroph adenomas, we recently found predominant mRNA expression of somatostatin (SS) receptor subtype 5… 
Highly Cited
2004
Highly Cited
2004
Functional gastroenteropancreatic tumors express all 5 somatostatin receptor subtypes (sst) in different quantities. Octreotide… 
Highly Cited
2004
Highly Cited
2004
Treatment with the somatostatin receptor (sst) subtype 2 predominant analogs octreotide and lanreotide induces clinical and… 
Highly Cited
2002
Highly Cited
2002
OBJECTIVE The aim of the present study was to identify a small, metabolically stable somatotropin release inhibiting factor (SRIF…